Middle East & Africa Breast Cancer Therapeutics Market Forecast to 2030

Middle East & Africa Breast Cancer Therapeutics Market Forecast to 2030

Middle East & Africa Breast Cancer Therapeutics Market Forecast to 2030 – Regional Analysis – by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)

Send Enquiry
Item ID: BMIRE00029750 Category: Tag:

$2,485 – $3,885

Description

The Middle East & Africa breast cancer therapeutics market was valued at US$ 762.61 million in 2022 and is expected to reach US$ 1,342.86 million by 2030; it is estimated to grow at a CAGR of 7.3% from 2022 to 2030.

Growing Burden of Breast Cancer Fuels the Middle East & Africa Breast Cancer Therapeutics Market

Breast cancer is considered the most common cancer among women worldwide, and its incidence is increasing globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and environmental factors contribute to the rising prevalence of breast cancer. According to WHO, in 2020, 685,000 people died worldwide from breast cancer, accounting for 2.3 million new diagnoses. Breast cancer is one of the most common cancers globally, with 7.8 million women alive as of the end of 2020 who had received a diagnosis within the previous five years. All across the world, breast cancer affects women at any age after adolescence. However, its prevalence rises with age. With the rise in breast cancer cases, there is an increasing need for effective and targeted therapies to improve patient outcomes. This has led to a surge in research and development activities in breast cancer therapeutics. Therefore, the growing burden of breast cancer drives the Middle East & Africa breast cancer therapeutics market.

Middle East & Africa Breast Cancer Therapeutics Market Overview

The breast cancer therapeutics market in the Middle East & Africa is segmented into UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Changing healthcare infrastructure and public-private partnerships between government and international players are strengthening the healthcare sector in the country. These partnerships and privatization efforts align with the policies included in the “Vision 2030” strategy by the Saudi government to transform the national economy. As per the International Trade Administration, the Saudi Arabian government invested about US$ 65 billion to build the country’s healthcare infrastructure as part of Vision 2030. In addition, it intends to increase private sector contribution from 40% to 65% by 2030, with a focus on the privatization of 290 hospitals and 2,300 primary health centers. Increased investment in infrastructure and innovation is anticipated to encourage growth in the market.

In June 2023, MSD GCC expanded its oncology research partnership with The Department of Health Abu Dhabi (DoH). The deal, signed at the BIO International Convention 2023, signified the continuation of a long-term collaboration between the two entities. Within the framework of their renewed partnership, the two parties will collaborate to initiate two observational research studies in the field of oncology, focusing on non-small cell lung cancer and triple-negative breast cancer. The studies aim to advance the ability to address the healthcare challenges associated with these diseases and improve patient outcomes. Therefore, the growing efforts of the companies to spread awareness and development of new and innovative products in the country significantly contribute to the growth of the breast cancer therapeutics market in the UAE.

In October 2021, the National Bank of Kuwait (NBK) launched an annual campaign to promote women’s health during breast cancer awareness month. The campaign is part of the Banks ongoing campaign to raise social awareness regarding breast cancer and promote its ways of prevention. Therefore, the above-mentioned factors significantly fuel the breast cancer therapeutics market growth.

Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Breast Cancer Therapeutics Market Segmentation

The Middle East & Africa breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the Middle East & Africa breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Middle East & Africa breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the Middle East & Africa breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the Middle East & Africa breast cancer therapeutics market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Middle East & Africa breast cancer therapeutics market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

,

Year of Publication:

At 7.3% CAGR, the Middle East & Africa Breast Cancer Therapeutics Market Is Speculated to be Worth US$ 1,342.86 Million by 2030, says the Research Team

According to the Research Team’ research, the Middle East & Africa breast cancer therapeutics market was valued at US$ 762.61 million in 2022 and is expected to reach US$ 1,342.86 million by 2030, registering a CAGR of 7.3% from 2022 to 2030. Increasing use of personalized medicine and rising cancer of breast cancer incidences are among the critical factors attributed to the Middle East & Africa breast cancer therapeutics market expansion.

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the Middle East & Africa breast cancer therapeutics market.

On the contrary, high cost of diagnosis and treatment hampers the growth Middle East & Africa breast cancer therapeutics market.

Based on drug therapy, the Middle East & Africa breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 61.5% share of the Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 468.82 million. It is projected to garner US$ 862.50 million by 2030 to expand at 7.9% CAGR during 2022-2030.

In terms of breast cancer type, the Middle East & Africa breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 66.4% share of the Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 506.30 million. It is projected to garner US$ 926.39 million by 2030 to expand at 7.8% CAGR during 2022-2030.

By distribution channel, the Middle East & Africa breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 74.4% share of Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 567.54 million. It is projected to garner US$ 1,020.91 million by 2030 to expand at 7.6% CAGR during 2022-2030.

Based on country, the Middle East & Africa breast cancer therapeutics market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia held 35.9% share of Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 273.43 million. It is projected to garner US$ 509.69 million by 2030 to expand at 8.1% CAGR during 2022-2030.

Key players operating in the Middle East & Africa breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.

– In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.

– In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa breast cancer therapeutics market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Breast Cancer Therapeutics Market – Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
6. Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Drug Therapy
6.1 Overview
6.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Middle East & Africa Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Middle East & Africa Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Breast Cancer Type
7.1 Overview
7.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Breast Cancer Therapeutics Market -Country Analysis
9.1 Middle East & Africa Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Middle East & Africa Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Middle East & Africa Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 Saudi Arabia
9.1.3.1.1 Saudi Arabia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 Saudi Arabia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 Saudi Arabia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 Saudi Arabia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 Saudi Arabia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 Saudi Arabia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 UAE
9.1.3.2.1 UAE Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 UAE: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 UAE: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 UAE: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 UAE: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 UAE: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 South Africa
9.1.3.3.1 South Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 South Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 South Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 South Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 South Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 South Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Rest of Middle East & Africa
9.1.3.4.1 Rest of Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

LIST OF TABLES

Table 1. Middle East & Africa Breast Cancer Therapeutics Market Segmentation
Table 2. Middle East & Africa Breast Cancer Therapeutics Market, by Targeted Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Breast Cancer Therapeutics Market, by Hormonal Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 4. Saudi Arabia Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 5. Saudi Arabia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 6. Saudi Arabia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 7. Saudi Arabia Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. Saudi Arabia Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 9. UAE Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 10. UAE Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 11. UAE Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 12. UAE Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. UAE Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. South Africa Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 15. South Africa Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 16. South Africa Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 17. South Africa Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. South Africa Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 19. Rest of Middle East & Africa Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 20. Rest of Middle East & Africa Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Middle East & Africa Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Middle East & Africa Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Middle East & Africa Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 24. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 25. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 26. Glossary of Terms, Breast Cancer Therapeutics Market

LIST OF FIGURES

Figure 1. Middle East & Africa Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Middle East & Africa Breast Cancer Therapeutics Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Middle East & Africa Breast Cancer Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 19. Middle East & Africa Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. Saudi Arabia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. UAE Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. South Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Rest of Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Growth Strategies in Breast Cancer Therapeutics Market

The List of Companies – Middle East & Africa Breast Cancer Therapeutics Market

1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc

Reviews

There are no reviews yet.

Be the first to review “Middle East & Africa Breast Cancer Therapeutics Market Forecast to 2030”